News
FDA asks Novavax for post-marketing data pledge amid stalled COVID shot review
On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and Research (CBER)—who resigned in March—warned that the mass downsizing at the agency could hamstring the regulator’s ability to review drugs beginning in 2026 or 2027.
Some key public health figures are taking an extraordinary step to try to shore up U.S. vaccination policy, feared to be ...
Over the next four months, the Vaccine Integrity Project will hold information-gathering sessions with medical associations, ...
Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...
The new FDA chief reiterated his commitment to speeding up drug approval processes and run the agency by “gold standard ...
New York Magazine on MSN4d
What It’s Like to Be a Vaccine Researcher in RFK Jr.’s AmericaHe is the head of HHS, and yet he continues to spout untested, unproven therapies and has only given a very lukewarm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback